Date
24 July 2017
Kim Kardashian has been telling her followers on Facebook, Twitter and Instagram to check out this morning sickness drug. Photo: NY Daily News
Kim Kardashian has been telling her followers on Facebook, Twitter and Instagram to check out this morning sickness drug. Photo: NY Daily News

How Kim Kardashian got a drug company in trouble

A drugnmaker is in trouble with US drug regulators thanks to reality star Kim Kardashian.

The watchdog has sent a warning letter to Duchesnay, a privately held Pennsylvania pharmaceutical company, after Kardashian endorsed its pills for morning sickness.

She took to Instagram, Twitter and Facebook last month to vouch for a medication called Diclegis, Bloomberg reports.

Kardashian said she was “partnering” with Duchesnay to raise awareness about morning sickness, urging her millions of social media followers to ask their doctors about the drug.

The company later sent a press release about the partnership.

The endorsement failed to include the necessary risk information and didn’t note limitations on the drug’s use.

That makes it misleading, accordign to the Food and Drug Administration.

The messages did include links to Web pages at which more complete safety information was available but the regulator says this isn’t enough.

Kardashian’s Instagram and Facebook posts couldn’t be located at the URLs the FDA cited, suggesting they may have been taken down.

As of midday on Tuesday, a tweet that linked to the Instagram endorsement was still live.

The FDA letter, dated Aug. 7, asked Duchesnay to “immediately cease misbranding” the drug or to stop selling it.

The agency gave the company until Aug. 21 to respond.

Diclegis is indicated for women who don’t respond to more conservative measures to address morning sickness such as eating more small meals or bland foods.

An earlier version of the compound known as Bendectin was withdrawn from the US market in 1983 over fears that it could cause birth defects, although the FDA later concluded that those concerns were unfounded.

– Contact us at [email protected]

RA

EJI Weekly Newsletter

Please click here to unsubscribe